Bridging unter Antikoagulation und Thrombozytenaggregationshemmung

Autor:	Mohammad Almalla, Ertunc Altiok
Rok vydání:	2020
Předmět:	business.industry Medicine Cardiology and Cardiovascular Medicine business
Zdroj:	Kardiologie up2date. 16:243-256
ISSN:	1860-3513 1611-6534
DOI:	10.1055/a-0886-2551
Popis:	AbtractWhen bridging anticoagulation, the risk of bleeding - compared to the thromboembolic risk - is often underestimated. Bridging is only indicated in case of high (and possibly moderate) thromboembolic risk. When bridging patients with indication for dual antiplatelet therapy, an interdisciplinary case discussion should take place to assess the risk.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae7bc299e0d2396808170192901f5781 https://doi.org/10.1055/a-0886-2551 Zobrazit plný text záznamu